Status:
COMPLETED
Determining the Effect of Abacavir on Platelet Activation
Lead Sponsor:
Bayside Health
Conditions:
HIV
Cardiovascular Disease
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
HIV positive patients have a two fold increased risk of developing cardiovascular disease (such as heart attacks and strokes). Cardiovascular disease appears to be due in part to both HIV and the side...
Eligibility Criteria
Inclusion
- \> 18 years of age
- Male
- HIV positive
- Stable non-abacavir containing anti-retroviral regimen
- Undetectable HIV Viral load
Exclusion
- HLA-B\*57\*01 allele positivity
- Previous allergy to abacavir
- Known cardiovascular disease
- High Baseline cardiovascular risk (Framingham risk score \> 20%)
- Current or recent antiplatelet therapy
- Pre-existing platelet or bleeding disorder (i.e. Thrombophilia, Thrombocytopenia, Von willebrands disease, Haemophilia)
- Significant Chronic liver disease
- Current Methadone use
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT01886638
Start Date
August 1 2013
End Date
October 1 2014
Last Update
May 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Health
Melbourne, Victoria, Australia, 3004